CompletedPhase 4

Effect of ALBIS on Gastroduodenal Mucosal Injury in Patients Receiving Dual Antiplatelet Therapy After Percutaneous Coronary Intervention

South Korea47 participantsStarted 2015-01-21

Plain-language summary

The purpose of this study is to evaluate effectiveness of ALBIS on Gastroduodenal Mucosal Injury in Patients Receiving Dual Antiplatelet Therapy after Percutaneous Coronary Intervention.

Who can participate

Age range

20 Years – 80 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age between 20 and 80 years * Patients undergoing percutaneous coronary intervention and need to take dual antiplatelet therapy continuously at least 12weeks * Modified Lanza Score grade 0-1 measured by upper gastrointestinal endoscopy * mild gastrointestinal symptom * Creatinen in blood ≤ 3mg/dl * BUN ≤ 50mg/dl * Birilubin ≤ 3mg/dl * AST and ALT ≤ 80U/L Exclusion Criteria: * Pregnant or breast feeding * History of Stomach or esophagus surgery * Peptic ulcer or reflux esophagitis * Zollinger-Ellison syndrome or primary esophageal motility disorders * Malignant tumor * Bleeding tendency or coagulopathy * Contraindication of ALBIS * Long term use of aspirin or P2Y12 receptor antagonist within 1month * Patients who tool medicine such as PPI, APA,H2blocker, Muscarine receptor antagonist, anti-gastic agent, antacid, anticaogulant, Bisphosphonate agents, Cytotoxic drug, NSAID, adrenal cortex hormone agents (topical treatment is allowed) * Terminal patient

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Incidence of gastric ulcer

Timeframe: 12weeks

Trial details

NCT IDNCT02175186

SponsorYoung-Hak Kim, MD, PhD

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2018-12-01

View on ClinicalTrials.gov More Gastritis trials

Who can participate

Age range

20 Years – 80 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.